Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide

NCT01300793 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped closed for low accrual and no data is available.

Conditions

Non-Hodgkin's Lymphoma
B-cell Lymphoma

Interventions

DRUG: Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide

Sponsor

University of California, San Francisco

Collaborators

[object Object]